Answer
Durvalumab is not recommended during pregnancy because its mechanism may disrupt pregnancy maintenance and cause foetal harm, with increased foetal loss after PD-L1 signalling disruption in mice and placental transfer confirmed in animals, although durvalumab animal studies did not indicate reproductive toxicity and human pregnancy data are absent.
Sources for this answer
- IMFINZI 50 mg/mL concentrate for solution for infusionAstraZeneca UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 38Document updated
Sources checked